International Assets Investment Management’s Coherus Oncology CHRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$61.9K Buy
42,958
+550
+1% +$898 ﹤0.01% 1245
2026
Q1
$73.8K Sell
42,408
-2,400
-5% -$4.26K 0.01% 1102
2025
Q4
$63.6K Sell
44,808
-906
-2% -$1.32K ﹤0.01% 1136
2025
Q3
$34.8K Hold
45,714
﹤0.01% 815
2025
Q2
$33.4K Buy
+45,714
New +$39.5K ﹤0.01% 831
2025
Q1
Sell
-45,606
Closed -$63.8K 785
2024
Q4
$63.8K Sell
45,606
-1,993
-4% -$2.24K 0.01% 798
2024
Q3
$45.8K Buy
47,599
+5,381
+13% +$7.38K 0.13% 160
2024
Q2
$73K Buy
42,218
+500
+1% +$1.01K 0.01% 1045
2024
Q1
$100K Sell
41,718
-1,072
-3% -$2.64K 0.01% 731
2023
Q4
$142K Buy
42,790
+29,014
+211% +$77.7K 0.02% 660
2023
Q3
$54.7K Buy
+13,776
New +$63.6K 0.01% 587

Other funds holding CHRS

International Assets Investment Management's CHRS Position: Q2 2026 in Review

International Assets Investment Management increased its Coherus Oncology (CHRS) stake by 1.3% in Q2 2026, buying an estimated $898 and bringing the position to 42,958 shares worth $61.9K. The position accounts for ﹤0.01% of the portfolio, ranked #1245.

International Assets Investment Management first reported a position in CHRS in Q3 2023 and has held it in 11 quarters since. The position peaked at $142K in Q4 2023. 27 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

  • International Assets Investment Management held 42,958 shares of Coherus Oncology worth $61.9K as of Q2 2026.
  • International Assets Investment Management bought 550 Coherus Oncology shares in Q2 2026, an estimated $898.
  • Coherus Oncology made up ﹤0.01% of International Assets Investment Management's portfolio in Q2 2026, its #1245 holding.
  • International Assets Investment Management first reported a position in Coherus Oncology in Q3 2023 and has held it in 11 quarters since.
  • International Assets Investment Management's Coherus Oncology position peaked at $142K in Q4 2023.
  • 27 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on International Assets Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.